Project Grant 2451302
Award Date 10/1/25
Completion Date 9/30/26
Dollars Obligated $305K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Carlos, CA 94070, USA
Similar Awards
- This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
- This SBIR Phase I project, awarded $305,000 by the National Science Foundation (CFDA 47.084 - Technology, Innovation, and Partnerships program), is developing novel peptide immunomodulators for treating autoimmune and inflammatory disorders. The project aims to create a new class of therapeutic compounds capable of effectively treating autoimmune diseases, including rare pediatric conditions like juvenile idiopathic arthritis-associated uveitis and pediatric Crohn's disease, without compromising...
- This SBIR Phase I federal grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $305,000 to Plexymer, Inc. to develop an AI-directed automation platform for accelerated bioformulation of antibody therapeutics. The project aims to streamline the process of transitioning hospital-administered antibody infusions to self-administered subcutaneous injections, potentially reducing formulation time and material use by up to 50%. By...
- This National Science Foundation Project Grant of $255,927 awarded to Invvax, Inc. on March 1, 2022 seeks to develop stable prophylactic antibodies through February 2023. Funded through the NSF Engineering Directorate's CFDA 47.041 program, this Small Business Innovation Research Phase I project will engineer mutations to antibody Fc regions to resist degradation and enhance binding to the neonatal Fc receptor for potentially decades-long duration. Specifically, the awardee will combine known...
- This $274,975 Small Business Innovation Research (SBIR) Phase I grant awarded by the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) supports the development of an antibody therapy targeting neoantigens in acute myeloid leukemia (AML). The project aims to create a platform technology that combines cancer-specific antibodies and adoptive natural killer (NK) immune cells to achieve high efficacy and low toxicity in treating relapsed/refractory AML. Key...
- This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Genexgen Inc., a small disadvantaged business, is providing $274,763 to develop an mRNA-based tolerogenic vaccine to address immune response challenges in viral-based gene therapies. The proposed solution aims to train the immune system to ignore antigens expressed in gene therapy treatments, enabling higher and more persistent therapeutic protein expression. This could...
- This $274,797 National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Deepseq.ai LLC supports the development of an AI-driven platform to accelerate the identification of highly developable single-domain antibodies for drug discovery. The proposed work aims to create a multimodal AI model capable of rapidly screening large libraries to generate lead molecules with favorable binding affinity, stability, and manufacturability. This project...
- This STTR Phase I project, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a novel vaccine platform to provide longer-lasting protection against infectious diseases. The $304,438 grant, awarded on October 1, 2025, supports Nitro Biosciences Inc.'s research to overcome limitations associated with immune imprinting, where prior exposure to pathogens can bias immune responses away from protective...
- This $256,000 National Science Foundation project grant supports the generation of directly active monoclonal antibodies to CD19 for the treatment of B-cell malignancies by Welt Bio-Molecular Pharmaceutical, LLC. The grant funds research under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop novel monoclonal antibody therapies that could provide more affordable and less toxic options for leukemias and lymphomas compared to current drugs. Specifically, the awardee...